サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1390755

胃不全まひ治療薬市場：世界の産業動向、シェア、規模、成長、機会、2023-2028年予測

Gastroparesis Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028
出版日: | 発行: IMARC | ページ情報: 英文 149 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.95円
胃不全まひ治療薬市場：世界の産業動向、シェア、規模、成長、機会、2023-2028年予測
出版日: 2023年11月24日
発行: IMARC
ページ情報: 英文 149 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

概要

胃不全まひ治療薬の世界市場規模は2022年に62億米ドルに達しました。今後、IMARCグループは、2022年から2028年にかけて4.77%の成長率（CAGR）を示し、2028年までに82億米ドルに達すると予測しています。

胃不全まひは、胃の筋肉の正常な自発的運動に影響を及ぼす病状です。消化プロセスを妨げ、吐き気、嘔吐、腹痛、血糖値の維持や栄養吸収の問題を引き起こします。現在、胃不全まひは、ドンペリドン、メトクロプラミド、エリスロマイシン、ジフェンヒドラミン、オンダンセトロン、プロクロルペラジンなどの薬剤を用いて、医師の指導の下で治療されています。

胃不全まひ治療薬の市場動向：

急速な都市化、座りがちなライフスタイル、常飲・常喫者の増加により、世界中で糖尿病の有病率が大幅に上昇しています。これは、胃不全まひを発症しやすい老年人口の増加と相まって、市場の成長を後押しする主な要因の一つとなっています。さらに、胃不全まひ治療薬は、収縮の頻度を改善することによって胃腸の運動を高めるのを助ける。その結果、激しい嘔吐、吐き気、上腹部痛を引き起こす特発性胃不全まひの治療に広く利用されています。これに加えて、外科手術によって漠然とした神経とその枝が損傷された後に胃不全まひを発症する人の数がかなり増加していることも、市場の成長に寄与しています。さらに、大手メーカーは既存の薬物療法に新たなアプローチを導入するため、研究開発（R&D）プロジェクトに継続的に資金を提供しています。彼らはまた、胃不全まひの症状を経験している個人のために鼻腔を介して投与することができる高度で効果的な薬剤を開発しており、これは良好な市場の見通しを作成しています。その他、ヘルスケアインフラの改善やユーザーフレンドリーな薬剤への需要の高まりなどが、市場の成長に拍車をかけると予想されます。

本レポートで扱う主な質問

  • 2022年の胃不全まひ治療薬の世界市場規模は？
  • 2023-2028年の胃不全まひ治療薬の世界市場成長率は？
  • COVID-19が胃不全まひ治療薬の世界市場に与えた影響は？
  • 胃不全まひ治療薬の世界市場を牽引する主要因は？
  • 疾患タイプ別の胃不全まひ治療薬の世界市場の内訳は？
  • 薬剤クラス別の胃不全まひ治療薬の世界市場内訳は？
  • 販売チャネル別の胃不全まひ治療薬の世界市場内訳は？
  • 胃不全まひ治療薬の世界市場における主要地域は？
  • 胃不全まひ治療薬の世界市場における主要プレイヤー/企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査目的
  • 利害関係者
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要産業動向

第5章 胃不全まひ治療薬の世界市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：疾患タイプ別

  • 糖尿病性胃不全まひ
    • 市場動向
    • 市場予測
  • 特発性胃不全まひ
    • 市場動向
    • 市場予測
  • 術後胃不全まひ
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第7章 市場内訳：薬剤クラス別

  • 運動促進剤
    • 市場動向
    • 市場予測
  • 制吐剤
    • 市場動向
    • 市場予測
  • ボツリヌス毒素注射剤
    • 市場動向
    • 市場予測

第8章 市場内訳：流通チャネル別

  • 病院・クリニック
    • 市場動向
    • 市場予測
  • 薬局
    • 市場動向
    • 市場予測
  • オンラインストア
    • 市場動向
    • 市場予測

第9章 市場内訳：地域別

  • 北米
    • 米国
      • 市場動向
      • 市場予測
    • カナダ
      • 市場動向
      • 市場予測
  • アジア太平洋
    • 中国
      • 市場動向
      • 市場予測
    • 日本
      • 市場動向
      • 市場予測
    • インド
      • 市場動向
      • 市場予測
    • 韓国
      • 市場動向
      • 市場予測
    • オーストラリア
      • 市場動向
      • 市場予測
    • インドネシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 欧州
    • ドイツ
      • 市場動向
      • 市場予測
    • フランス
      • 市場動向
      • 市場予測
    • 英国
      • 市場動向
      • 市場予測
    • イタリア
      • 市場動向
      • 市場予測
    • スペイン
      • 市場動向
      • 市場予測
    • ロシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • ラテンアメリカ
    • ブラジル
      • 市場動向
      • 市場予測
    • メキシコ
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 中東・アフリカ地域
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第10章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第13章 価格分析

第14章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Abbott Laboratories
    • Abbvie Inc.
    • AstraZeneca Plc
    • Bausch Health Companies Inc.
    • Becton Dickinson and Company
    • Boston Scientific Corporation
    • Evoke Pharma
    • Medtronic plc
    • Neurogastrx Inc.
    • Sanofi S.A.
    • Takeda Pharmaceutical Company Limited
    • Theravance Biopharma
図表

List of Figures

  • Figure 1: Global: Gastroparesis Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Gastroparesis Drugs Market: Sales Value (in Billion US$), 2017-2022
  • Figure 3: Global: Gastroparesis Drugs Market Forecast: Sales Value (in Billion US$), 2023-2028
  • Figure 4: Global: Gastroparesis Drugs Market: Breakup by Disease Type (in %), 2022
  • Figure 5: Global: Gastroparesis Drugs Market: Breakup by Drug Class (in %), 2022
  • Figure 6: Global: Gastroparesis Drugs Market: Breakup by Distribution Channel (in %), 2022
  • Figure 7: Global: Gastroparesis Drugs Market: Breakup by Region (in %), 2022
  • Figure 8: Global: Gastroparesis Drugs (Diabetic Gastroparesis) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 9: Global: Gastroparesis Drugs (Diabetic Gastroparesis) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 10: Global: Gastroparesis Drugs (Idiopathic Gastroparesis) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 11: Global: Gastroparesis Drugs (Idiopathic Gastroparesis) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 12: Global: Gastroparesis Drugs (Post-surgical Gastroparesis) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 13: Global: Gastroparesis Drugs (Post-surgical Gastroparesis) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 14: Global: Gastroparesis Drugs (Other Disease Types) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 15: Global: Gastroparesis Drugs (Other Disease Types) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 16: Global: Gastroparesis Drugs (Prokinetic Agents) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 17: Global: Gastroparesis Drugs (Prokinetic Agents) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 18: Global: Gastroparesis Drugs (Antiemetic Agents) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 19: Global: Gastroparesis Drugs (Antiemetic Agents) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 20: Global: Gastroparesis Drugs (Botulinum Toxin Injections) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 21: Global: Gastroparesis Drugs (Botulinum Toxin Injections) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 22: Global: Gastroparesis Drugs (Hospitals and Clinics) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 23: Global: Gastroparesis Drugs (Hospitals and Clinics) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 24: Global: Gastroparesis Drugs (Pharmacies) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 25: Global: Gastroparesis Drugs (Pharmacies) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 26: Global: Gastroparesis Drugs (Online Stores) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 27: Global: Gastroparesis Drugs (Online Stores) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 28: North America: Gastroparesis Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 29: North America: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 30: United States: Gastroparesis Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 31: United States: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 32: Canada: Gastroparesis Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 33: Canada: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 34: Asia-Pacific: Gastroparesis Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 35: Asia-Pacific: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 36: China: Gastroparesis Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 37: China: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 38: Japan: Gastroparesis Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 39: Japan: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 40: India: Gastroparesis Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 41: India: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 42: South Korea: Gastroparesis Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 43: South Korea: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 44: Australia: Gastroparesis Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 45: Australia: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 46: Indonesia: Gastroparesis Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 47: Indonesia: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 48: Others: Gastroparesis Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 49: Others: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 50: Europe: Gastroparesis Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 51: Europe: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 52: Germany: Gastroparesis Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 53: Germany: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 54: France: Gastroparesis Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 55: France: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 56: United Kingdom: Gastroparesis Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 57: United Kingdom: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 58: Italy: Gastroparesis Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 59: Italy: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 60: Spain: Gastroparesis Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 61: Spain: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 62: Russia: Gastroparesis Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 63: Russia: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 64: Others: Gastroparesis Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 65: Others: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 66: Latin America: Gastroparesis Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 67: Latin America: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 68: Brazil: Gastroparesis Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 69: Brazil: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 70: Mexico: Gastroparesis Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 71: Mexico: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 72: Others: Gastroparesis Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 73: Others: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 74: Middle East and Africa: Gastroparesis Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 75: Middle East and Africa: Gastroparesis Drugs Market: Breakup by Country (in %), 2022
  • Figure 76: Middle East and Africa: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 77: Global: Gastroparesis Drugs Industry: SWOT Analysis
  • Figure 78: Global: Gastroparesis Drugs Industry: Value Chain Analysis
  • Figure 79: Global: Gastroparesis Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Gastroparesis Drugs Market: Key Industry Highlights, 2022 and 2028
  • Table 2: Global: Gastroparesis Drugs Market Forecast: Breakup by Disease Type (in Million US$), 2023-2028
  • Table 3: Global: Gastroparesis Drugs Market Forecast: Breakup by Drug Class (in Million US$), 2023-2028
  • Table 4: Global: Gastroparesis Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2023-2028
  • Table 5: Global: Gastroparesis Drugs Market Forecast: Breakup by Region (in Million US$), 2023-2028
  • Table 6: Global: Gastroparesis Drugs Market: Competitive Structure
  • Table 7: Global: Gastroparesis Drugs Market: Key Players
目次
Product Code: SR112023A4608

Abstract

The global gastroparesis drugs market size reached US$ 6.2 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 8.2 Billion by 2028, exhibiting a growth rate (CAGR) of 4.77% during 2022-2028.

Gastroparesis, also known as stomach paralysis, is a medical condition that affects the normal and spontaneous movement of the muscles in the stomach. It interferes with the digestion process and causes nausea, vomiting, abdominal pain, and problems with maintaining blood sugar levels and nutrition absorption. At present, it is treated under the guidance of doctors using drugs, such as domperidone, metoclopramide, erythromycin, diphenhydramine, ondansetron, and prochlorperazine.

Gastroparesis Drugs Market Trends:

Due to rapid urbanization, sedentary lifestyles and the growing number of individuals who drink and smoke regularly, there is a significant rise in the prevalence of diabetes across the globe. This, in confluence with the increasing geriatric population, which is relatively more susceptible to developing gastroparesis, represents one of the key factors bolstering the growth of the market. In addition, gastroparesis drugs aid in enhancing gastrointestinal motility by improving the frequency of contraction. As a result, they are extensively being utilized for treating idiopathic gastroparesis, which causes severe vomiting, nausea, and upper abdominal pain. This, along with a considerable rise in the number of individuals developing gastroparesis after the vague nerve and its branches are damaged via surgical operations, are also contributing to market growth. Furthermore, leading manufacturers are continuously funding research and development (R&D) projects to introduce new approaches to the existing drug therapy. They are also developing advanced and effective drugs that can be administered via the nasal cavity for individuals who are experiencing symptoms of gastroparesis, which is creating a favorable market outlook. Other major factors, including the improving healthcare infrastructure and the escalating demand for user-friendly drugs, are anticipated to impel the growth of the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global gastroparesis drugs market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on disease type, drug class and distribution channel.

Breakup by Disease Type:

Diabetic Gastroparesis

Idiopathic Gastroparesis

Post-surgical Gastroparesis

Others

Breakup by Drug Class:

Prokinetic Agents

Antiemetic Agents

Botulinum Toxin Injections

Breakup by Distribution Channel:

Hospitals and Clinics

Pharmacies

Online Stores

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Abbvie Inc., AstraZeneca Plc, Bausch Health Companies Inc., Becton Dickinson and Company, Boston Scientific Corporation, Evoke Pharma, Medtronic plc, Neurogastrx Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited and Theravance Biopharma.

Key Questions Answered in This Report

  • 1. What was the size of the global gastroparesis drugs market in 2022?
  • 2. What is the expected growth rate of the global gastroparesis drugs market during 2023-2028?
  • 3. What has been the impact of COVID-19 on the global gastroparesis drugs market?
  • 4. What are the key factors driving the global gastroparesis drugs market?
  • 5. What is the breakup of the global gastroparesis drugs market based on the disease type?
  • 6. What is the breakup of the global gastroparesis drugs market based on the drug class?
  • 7. What is the breakup of the global gastroparesis drugs market based on the distribution channel?
  • 8. What are the key regions in the global gastroparesis drugs market?
  • 9. Who are the key players/companies in the global gastroparesis drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Gastroparesis Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Disease Type

  • 6.1 Diabetic Gastroparesis
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Idiopathic Gastroparesis
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Post-surgical Gastroparesis
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Others
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Drug Class

  • 7.1 Prokinetic Agents
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Antiemetic Agents
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Botulinum Toxin Injections
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Distribution Channel

  • 8.1 Hospitals and Clinics
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Pharmacies
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Online Stores
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Abbott Laboratories
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Abbvie Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 AstraZeneca Plc
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Bausch Health Companies Inc.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Becton Dickinson and Company
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Boston Scientific Corporation
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Evoke Pharma
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
    • 14.3.8 Medtronic plc
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Neurogastrx Inc.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
    • 14.3.10 Sanofi S.A.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
    • 14.3.11 Takeda Pharmaceutical Company Limited
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis
    • 14.3.12 Theravance Biopharma
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
      • 14.3.12.3 Financials
      • 14.3.12.4 SWOT Analysis